Development of transformative therapies for the treatment of whorsening and accute decompensated heart failure
Location: France, Ile-of-France, Paris
Employees: 1-10
Total raised: $69.6M
Founded date: 2021
Investors 4
| Date | Name | Website |
| 01.11.2023 | Jeito Capi... | jeito.life |
| 27.11.2023 | V-Bio Vent... | v-bio.vent... |
| 30.10.2023 | Kurma Part... | kurmapartn... |
| 25.10.2023 | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2023 | Series A | $69.6M | - |
Mentions in press and media 4
| Date | Title | Description |
| 08.09.2023 | France-based Corteria Pharmaceuticals raises EUR 65 million in funding | Paris, France-based biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, Corteria Pharmaceuticals raises EUR 65 million in Series A financing. The round took plac... |
| 07.09.2023 | Corteria Pharmaceuticals Raises €65M in Series A Funding | Corteria Pharmaceuticals, a Paris, France-based biopharmaceutical company specialized in the development of therapies for unaddressed heart failure subpopulations, raised €65M in Series A funding. The round was led by OrbiMed and Jeito Capi... |
| 07.09.2023 | Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases | Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M) Series A co-led by US ... |
| 21.10.2022 | Corteria Pharmaceuticals strengthens its Executive Leadership Team, Board of Directors, and Scientific Advisory Board | Corteria Pharmaceuticals, a biotechnology company developing innovative treatments for certain forms of heart failure, announced today the recruitment of Dr. Francesca C. Lawson as Chief Medical Officer. Corteria Pharmaceuticals also expand... |